Yukihiro Kitanaga
Tsukuba, 3058585, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A novel retinoic acid receptor-α inhibitor, AS4040605, inhibits ILC2 activity.
Journal: European journal of pharmacology
Published: January 07, 2025
Preclinical Characterization of ASP2713, a Novel Igβ and FcγRIIB Cross-Linking Antibody, for Prediction of Human Pharmacokinetics and Clinically Effective Dose.
Journal: Journal of pharmaceutical sciences
Published: February 10, 2022
Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus.
Journal: International immunopharmacology
Published: September 06, 2021
Kdm5a promotes B cell activation in systemic lupus erythematosus via downregulation of A20 by histone modification.
Journal: Pathology, research and practice
Published: July 16, 2021
Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis.
Journal: Rheumatology (Oxford, England)
Published: October 15, 2020
In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
Journal: Rheumatology (Oxford, England)
Published: July 08, 2019
Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus.
Journal: Clinical immunology (Orlando, Fla.)
Published: August 02, 2018
Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System.
Journal: Frontiers in immunology
Published: February 17, 2018
Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.
Journal: Annals of the rheumatic diseases
Published: November 04, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026